Date | Company | Round | Amount | Co-investors |
---|---|---|---|---|
2020-10-30 | Dmall | Series C | $418.55M | China Structural Reform Fund, CMB International Capital, Hengan International, IDG Capital, Lenovo Capital and Incubator Group, Shenzhen Futian Guiding Fund, Tencent Holdings, and Tianya Capital |
2020-08-19 | LP Pharmaceuticals | Series C | $72.34M | DYEE Capital, Fujian Investment and Development, Guigu Huoju Fund, Lapam Capital, Qian Dao Fund, Sequoia Capital China, Shenzhen Capital Group, and Zhongjin Chuanhua |
2020-07-10 | NIO China | Line of Credit | $1.48603B | Agricultural Bank of China, Bank of China, China Construction Bank, China Merchants Bank, and Industrial and Commercial Bank of China |
2020-06-23 | Guangdong Tiannuo Minbao | Corporate Minority | $0.94M | |
2020-05-25 | Galaxis | Series D | China Capital Investment Group, Huagai Capital, Oriza Equity Investment, SinoKing Capital, Sumin Investment, and V-Capital |